Marine Drugs (Feb 2022)

Aurasperone A Inhibits SARS CoV-2 In Vitro: An Integrated In Vitro and In Silico Study

  • Mai H. ElNaggar,
  • Ghada M. Abdelwahab,
  • Omnia Kutkat,
  • Mohamed GabAllah,
  • Mohamed A. Ali,
  • Mohamed E. A. El-Metwally,
  • Ahmed M. Sayed,
  • Usama Ramadan Abdelmohsen,
  • Ashraf T. Khalil

DOI
https://doi.org/10.3390/md20030179
Journal volume & issue
Vol. 20, no. 3
p. 179

Abstract

Read online

Several natural products recovered from a marine-derived Aspergillus niger were tested for their inhibitory activity against SARS CoV-2 in vitro. Aurasperone A (3) was found to inhibit SARS CoV-2 efficiently (IC50 = 12.25 µM) with comparable activity with the positive control remdesivir (IC50 = 10.11 µM). Aurasperone A exerted minimal cytotoxicity on Vero E6 cells (CC50 = 32.36 mM, SI = 2641.5) and it was found to be much safer than remdesivir (CC50 = 415.22 µM, SI = 41.07). To putatively highlight its molecular target, aurasperone A was subjected to molecular docking against several key-viral protein targets followed by a series of molecular dynamics-based in silico experiments that suggested Mpro to be its primary viral protein target. More potent anti-SARS CoV-2 Mpro inhibitors can be developed according to our findings presented in the present investigation.

Keywords